NCT02420860 2026-04-15
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
57 trialsNCT04978584 2026-04-15
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03269669 2026-04-13
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03500445 2026-04-13
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT04133636 2026-04-13
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT06169215 2026-04-13
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06577025 2026-04-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05660967 2026-04-08
EPCORE DLBCL-3
Genmab
Phase 2 Active not recruiting
NCT01522976 2026-03-31
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04876248 2026-03-31
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT04268498 2026-03-24
ADVANCE
University of Miami
Phase 2 Active not recruiting
NCT06353022 2026-03-17
IFm2022-01
Nantes University Hospital
Phase 2 Active not recruiting
NCT05690984 2026-03-16
EMAT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT04151667 2026-03-11
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT02446457 2026-03-09
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04802356 2026-03-05
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
PETHEMA Foundation
Phase 2 Active not recruiting
NCT05090566 2026-02-23
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Active not recruiting
NCT06723457 2026-02-17
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Northwestern University
Phase 2 Active not recruiting
NCT04113018 2026-02-03
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT05497804 2026-02-03
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
Phase 2 Active not recruiting
NCT04430894 2026-01-29
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT01446133 2026-01-27
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04653246 2025-12-23
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04009109 2025-12-18
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT03290950 2025-12-15
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02523040 2025-12-10
Lenalidomide for Adult Histiocyte Disorders
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04174196 2025-12-02
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT01351896 2025-11-20
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02253316 2025-11-10
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04126200 2025-11-06
DREAMM5
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04497961 2025-09-11
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03004287 2025-09-10
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT01559935 2025-09-08
CarBiRD
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT03314636 2025-08-08
CONPET
Oslo University Hospital
Phase 2 Active not recruiting
NCT04635189 2025-08-08
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
University of Rochester
Phase 2 Active not recruiting
NCT04052880 2025-07-20
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
Icahn School of Medicine at Mount Sinai
Phase 2 Active not recruiting
NCT05123131 2025-07-08
Isa-RVD
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT02538198 2025-07-03
Lenalidomide Maintenance in Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04775550 2025-07-02
PRISM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT01816971 2025-06-10
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT03863184 2025-06-06
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT04460248 2025-05-02
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Ruijin Hospital
Phase 2 Active not recruiting
NCT03556332 2025-04-29
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04891809 2025-04-10
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Active not recruiting
NCT01415752 2025-04-08
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03376672 2025-04-03
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
Helsinki University Central Hospital
Phase 2 Active not recruiting
NCT04717700 2025-03-18
SABLe
Odense University Hospital
Phase 2 Active not recruiting
NCT05669989 2025-01-23
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT04782687 2025-01-16
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
Phase 2 Active not recruiting
NCT05335018 2024-12-16
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Seoul National University Hospital
Phase 2 Active not recruiting